CoChat

Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study

Open access
Han, Seung Jin, Ha, Kyoung Hwa, Lee, Nami, Kim, Dae Jung · 2021 · Diabetes, Obesity and Metabolism
Cited by 86

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aim: To examine the real‐world cardiovascular effectiveness and safety associated with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment in older adults with type 2 diabetes. Materials and Methods: In this retrospective cohort study, older adults with type 2 diabetes (aged ≥65 years) were identified in the Korean National Health Insurance Service database from September 2014 to December 2016. In total, 408 506 new users of an SGLT2 inhibitor or DPP‐4 inhibitor were propensity score matched. Cox regression was used to estimate the hazard ratios (HR) and 95% confidence interval (CI) for outcomes of interest: hospitalization for heart failure (HHF), all‐cause death, myocardial infarction, stroke, diabetic ketoacidosis (DKA), bone fracture, severe hypoglycaemia, genital infection and urinary tract infection (UTI). Results: Compared with DPP‐4 inhibitors, new users of SGLT2 inhibitors had a lower risk of HHF (HR 0.86; 95% CI 0.76‐0.97), all‐cause death (HR 0.85; 95% CI 0.75‐0.98) and stroke (HR 0.86; 95% CI 0.77‐0.97), but a similar risk of myocardial infarction (HR 0.95; 95% CI 0.77‐1.19). The risks of DKA, bone fracture and severe hypoglycaemia were similar between both groups, although genital infection (HR 2.44; 95% CI 2.22‐2.67) and UTI (HR 1.05; 95% CI 1.00‐21.11) were more frequent among new users of SGLT2 inhibitors compared with DPP‐4 inhibitors. Conclusion: Our findings suggest that initiation of SGLT2 inhibitors offers cardiovascular disease protection and can be used safely in older adults with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14261

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 31

  1. 10.4093/dmj.2019.0067 · DOI
  2. 10.1007/s00592-015-0790-4 · DOI
  3. 10.1177/2042098615615472 · DOI · Paper page
  4. 10.1016/j.numecd.2014.05.012 · DOI
  5. 10.1016/S2213-8587(13)70050-0 · DOI · Paper page
  6. 10.1093/ageing/afz096 · DOI · Paper page
  7. 10.2337/dc19-1476 · DOI · Paper page
  8. 10.1016/j.numecd.2017.11.007 · DOI · Paper page
  9. 10.4093/dmj.2019.0137 · DOI · Paper page
  10. 10.1007/s00125-016-3971-y · DOI
  11. 10.1111/dom.12889 · DOI · Paper page
  12. Mitnitski A, 2017, Heterogeneity of human aging and its assessment, J Gerontol A Biol Sci Med Sci., 72, 877
  13. 10.1093/gerona/glr065 · DOI
  14. 10.1111/dom.13627 · DOI
  15. 10.1111/dom.13424 · DOI · Paper page
  16. 10.1016/j.jacc.2018.03.009 · DOI · Paper page
  17. 10.1111/dom.14025 · DOI
  18. 10.1161/CIRCULATIONAHA.117.031227 · DOI · Paper page
  19. 10.1016/j.jacc.2018.01.085 · DOI · Paper page
  20. 10.2337/diacare.27.3.699 · DOI · Paper page
  21. 10.1186/s12933-017-0575-x · DOI
  22. 10.1136/bmj.k119 · DOI · Paper page
  23. 10.1111/dom.13477 · DOI · Paper page
  24. 10.1136/bmj.l4772 · DOI · Paper page
  25. 10.1016/S2213-8587(20)30130-3 · DOI
  26. 10.1007/s00059-017-4668-9 · DOI
  27. 10.1111/dom.12825 · DOI · Paper page
  28. 10.1111/dom.13531 · DOI · Paper page
  29. 10.1111/dom.13820 · DOI · Paper page
  30. 10.4093/dmj.2013.37.4.233 · DOI
  31. 10.1186/s42444-019-0005-0 · DOI · Paper page

Cited by

Metadata

Authors
Han, S. J., Ha, K. H., Lee, N., & Kim, D. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-12-15
Volume
23
Issue
3
Pages
682-691
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3109783871
Cited by
86
References
13
FWCI
7.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.